Press Releases

DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceutical’s Lead Drug, CRV431
March 23, 2021

Hepion Pharmaceuticals Announces Presentation and Panel Participation at the Benzinga Global Biotech Small Cap Conference
March 22, 2021

Hepion Pharmaceuticals to Present on CRV431 and AI-POWR™ at NASH-TAG 2021
March 11, 2021

Hepion Pharmaceuticals, Inc. Announces Closing of Public Offering
February 18, 2021

Hepion Pharmaceuticals Announces Pricing of Public Offering
February 16, 2021

Hepion Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
February 12, 2021

Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer
February 10, 2021

Hepion Pharmaceuticals to Participate in BIO CEO & Investor Digital Conference
February 09, 2021

Hepion Pharmaceuticals to Participate in Upcoming January Virtual Investor Conferences
January 05, 2021

Hepion Pharmaceuticals Announces Positive Top Line Data for Low Dose CRV431 in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH
December 29, 2020